Evidence map›Paper›PMID 35777750›Full record

ArticleSouthern medical journal2022

Evaluation of the Effect of Biochemistry Parameters on the Clinical Course in COVID-19 Patients Who Received Tocilizumab Treatment.

Faysal Duksal, Cengiz Burnik, Mehmet Mermer, Serkan Yavuz

Open access · bronzeAbstract read
In one paragraph

Article in Southern medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Faysal DuksalFrom the Department of Chest Diseases and Tuberculosis; Beyhekim Research and Training Hospital, Konya, Turkey, and the Department of Chest Diseases and Tuberculosis, Konya City Hospital, Konya, Turkey.
Cengiz BurnikFrom the Department of Chest Diseases and Tuberculosis; Beyhekim Research and Training Hospital, Konya, Turkey, and the Department of Chest Diseases and Tuberculosis, Konya City Hospital, Konya, Turkey.
Mehmet MermerFrom the Department of Chest Diseases and Tuberculosis; Beyhekim Research and Training Hospital, Konya, Turkey, and the Department of Chest Diseases and Tuberculosis, Konya City Hospital, Konya, Turkey.
Serkan YavuzFrom the Department of Chest Diseases and Tuberculosis; Beyhekim Research and Training Hospital, Konya, Turkey, and the Department of Chest Diseases and Tuberculosis, Konya City Hospital, Konya, Turkey.
Konya Eğitim ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPatients who develop cytokine storm while they have coronavirus disease 2019 (COVID-19) experience more severe symptoms. This article aims to evaluate the effect of biochemical parameters on the clinical course of the disease in patients treated with tocilizumab (TCZ) due to cytokine storm.

methodsMedical documents of patients with COVID-19 were searched retrospectively. Patients who entered cytokine storm were classified as group 1 and divided into two subgroups as patients who were followed up in the ward and in the intensive care unit (ICU). Less severe COVID-19 patients who did not enter cytokine storm were included in the control group as group 2.

resultsA total of 522 patients with COVID-19 infection were included in the study. The mean age was 62.0 ± 15.6 years, and the majority were male (64.4%). Hypertension and diabetes mellitus were the two most common diseases, seen in 50.8% and 29.9%, respectively. There were 392 patients with TCZ application (group 1) and 130 patients without TCZ (group 2). Significantly higher serum glucose, magnesium, and sodium and lower calcium levels were present in group 1 than in group 2 (<0.001). Hypocalcemia, hypernatremia, hypermagnesemia, and hyperkalemia were more frequently detected in the ICU compared with the patients treated in the wards (

conclusionsFollowing up closely electrolyte disturbances may support patient survival and decrease the probability of ICU necessity. This approach should be taken before the development of important disorders to be effective in the treatment process of the main disease.

Indexed as

COVID-19 Drug TreatmentCytokine Release SyndromeAgedAntibodies, Monoclonal, HumanizedFemaleHumansMaleMiddle AgedRetrospective StudiesAntibodies, Monoclonal, Humanizedtocilizumab

Identifiers

PMID35777750
PMCPMC9232244
OpenAlexW4283778413

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.